|Bid||18.00 x 0|
|Ask||18.02 x 0|
|Day's Range||17.56 - 18.80|
|52 Week Range||9.45 - 23.25|
|PE Ratio (TTM)||40.62|
|Forward Dividend & Yield||0.07 (0.38%)|
|1y Target Est||22.84|
3SBio Inc’s (HKG:1530) released its most recent earnings update in December 2017, which confirmed that the company gained from a strong tailwind, leading to a double-digit earnings growth of 31.27%.Read More...
3SBio Inc., a Chinese biotech company that’s seen its revenue double in past two years, recently caught the eye of one of the world’s best performing global funds. Dynamic Power Global Growth Class -- the top performer among the 1,000 mutual funds investing globally in the past five years -- bought 17.4 million Hong Kong-listed shares of 3SBio a few months ago, making it the only Chinese healthcare stock in its $1.2 billion portfolio. “I’m always looking for companies where there is not only growth, but the ability to sustain that growth,” Noah Blackstein, the 48-old Canadian fund manager said in an interview last month when asked why Dynamic Power allocated about one third of its capital to Chinese stocks including 3SBio.
HONG KONG, March 26, 2018 /PRNewswire/ -- Leading Chinese biotechnology company 3SBio (01530.HK) today released its 2017 annual results, showing that the company has been dramatically growing with important progress made in all businesses. Looking to the future, the company intends to reinforce its position as a leading biopharmaceutical company in China by leveraging its integrated R&D, commercial, and manufacturing platforms. The company will also focus on developing leading biologics products that enable it to provide a variety of treatment options for patients.
Jan 15 (Reuters) - 3Sbio Inc: * UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820 Source text for Eikon: Further company ...
SHANGHAI, Jan. 4, 2018 /PRNewswire/ -- 3Sbio Inc. (01530.HK) announced today that China's first Glucagon-like peptide-1 (GLP-1) receptor agonist weekly preparation Bydureon® (generic name Exenatide Microsphere for injection) has been formally approved by China Food and Drug Administration (CFDA), as a new treatment option to improve glycemic control for patients with type 2 diabetes. As the first and currently the only GLP-1 medicine in China to be administered once-weekly, exenatide microsphere can reduce the frequency of dosing, reduce gastrointestinal adverse effects and increase drug stability and improve patient compliance by continuing to provide steady-state levels of exenatide with sustained release microsphere technology, which will provide a new treatment option for the majority of patients with type 2 diabetes in China.
SHENYANG China, Sept. 3, 2017 /PRNewswire/ -- 3SBio Inc. (01530.HK, the "Group"), a leading Chinese biopharmaceutical company, is pleased to announce today that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture (the "JV") shall be established. The Group and CPE Funds seek to position the JV as a global, comprehensive and biologics-focused contract development and manufacturing (CDMO) platform. On September 1st, the JV entered into an Asset Purchase Agreement with Canada-based biologics manufacturer Therapure Biopharma Inc. to acquire its CDMO business, Therapure Biomanufacturing, for US$290 million.
May.29 -- Bo Tan, chief financial officer at 3SBio, discusses the opportunities he's seeing in China's red-hot healthcare sector, the products in the company pipeline, approvals and regulation changes, competition and acquisitions. He speaks exclusively on "Bloomberg Markets: Asia" from the Morgan Stanley China summit in Beijing.